scispace - formally typeset
G

Guangxu Lan

Researcher at University of Chicago

Publications -  43
Citations -  3771

Guangxu Lan is an academic researcher from University of Chicago. The author has contributed to research in topics: Photodynamic therapy & Catalysis. The author has an hindex of 24, co-authored 37 publications receiving 2327 citations. Previous affiliations of Guangxu Lan include Peking University.

Papers
More filters
Journal ArticleDOI

Nanoscale Metal-Organic Framework Overcomes Hypoxia for Photodynamic Therapy Primed Cancer Immunotherapy.

TL;DR: A nanoscale metal-organic framework, Fe-TBP, is reported as a novel nanophotosensitizer to overcome tumor hypoxia and sensitize effective PDT, priming non-inflamed tumors for cancer immunotherapy.
Journal ArticleDOI

Low-dose X-ray radiotherapy–radiodynamic therapy via nanoscale metal–organic frameworks enhances checkpoint blockade immunotherapy

TL;DR: By combining the advantages of local radiotherapy and systemic tumour rejection via synergistic X-ray-induced in situ vaccination and indoleamine 2,3-dioxygenase inhibition, nMOFs may overcome some of the limitations of checkpoint blockade in cancer treatment.
Journal ArticleDOI

Nanoscale Metal-Organic Frameworks for Phototherapy of Cancer.

TL;DR: This review summarizes recent advances on using nMOFs as nanoparticle PSs for applications in PDT and PTT and highlights the importance of efficient and selective delivery of PSs to the diseased tissues.
Journal ArticleDOI

Nanoscale metal-organic frameworks enhance radiotherapy to potentiate checkpoint blockade immunotherapy

TL;DR: The design of two porous Hf-based nanoscale metal-organic frameworks (nMOFs) as highly effective radioenhancers that significantly outperform HfO2, a clinically investigated radioenhancer in vitro and in vivo are reported.
Journal ArticleDOI

Titanium-Based Nanoscale Metal-Organic Framework for Type I Photodynamic Therapy.

TL;DR: The design of a new nMOF, Ti-TBP, composed of Ti-oxo chain secondary building units (SBUs) and photosensitizing 5,10,15,20-tetra( p-benzoato)porphyrin (TBP) ligands, for hypoxia-tolerant type I PDT, which elicits superb anticancer efficacy with >98% tumor regression and 60% cure rate.